Pharmaceutical Newsletter – April 04 to 08, 2016

Lupin is eyeing acquisitions in Japan to get ahead of rivals such as Sun Pharma. Pfizer terminated the merger with Allergan. NPPA capped Hepatitis C drug 'Sofosbuvir' at Rs. 619.31 per tablet. Here are the key highlights for the week.

April 08, 2016 5:07 IST | India Infoline News Service
Top News
Pfizer terminates US$ 160 bn merger with Allergan
Pfizer Inc. today announced that the merger agreement between Pfizer and Allergan plc has been terminated by mutual agreement of the companies. Read more

NPPA caps Hepatitis C drug’s price to Rs. 619.31 per pill
National Pharmaceutical Pricing Authority (NPPA), the drug pricing regulator, has capped the price of blockbuster Hepatitis C drug 'Sofosbuvir' at Rs. 619.31 per tablet. Read more

Lupin eyes acquisition in Japan to counter Sun Pharma
Lupin Ltd is looking for acquisitions in Japan to maintain its lead in a bid to counter the threat from the entry of Sun Pharmaceutical Industries in that market, reports a business daily. Read more

Cipla eyes on speciality drugs in US
Cipla is planning to deploy more funds for research and development in respiratory, dermatology, neurology and oncology segments, says report. Read more

News in Focus
Govt mulling pharma zones to reduce API imports: Nirmala Sitharaman
The Government is considering setting up specified pharmaceutical zones to boost domestic manufacture of active pharmaceutical ingredients (APIs), in order to reduce the country’s dependence on China for the raw material, Commerce Minister Nirmala Sitharaman said on Tuesday. Read more

Domestic News
USFDA issues 3 observation for Lupin’s Aurangabad facility
The United State Food and Drug Administration (USFDA) has issued 3 observations to Lupin for its Aurangabad plant. Read more

Lupin launches first product from GAVIS pipeline, exclusivity of 180 days
Pharma major Lupin announced that its US subsidiary, Lupin Pharmaceuticals Inc. (collectively Lupin) has launched the first product from its GAVIS pipeline, Zolpidem Sublingual Tablets, 1.75 mg & 3.5 mg to market a generic equivalent of Purdue Pharma L.P’s Intermezzo Sublingual Tablets, 1.75 mg & 3.5 mg, having received final approval from the United States Food & Drug Administration (FDA) earlier, as well as final clearance from the FTC with 180 days of exclusivity. Read more

Dr Reddy's Lab recalls 3,342 vials of osteoporosis injection in US
Dr Reddy's Laboratories US arm is recalling 3,342 vials of anti-osteoporosis injection, made by Gland Pharma, according to reports. Read more

Gland Pharma attracts bids from Torrent Pharma, Baxter
Hyderabad-based specialty injectable drugmaker Gland Pharma has attracted bids from top drugmakers, includingTorrent Pharma and US-based Baxter. Read more

KKR may sell its 40% stake in Gland Pharma
KKR may sell its 40% stake in the Hyderabad-based Gland Pharma as part of the deal, reported CNBC TV18. Read more

IPCA Lab says Geneva-based fund stops buying its anti-malaria drugs
IPCA Laboratories Limited has announced that "The Global Fund, Geneva, Switzerland vide their letter dated April 04, 2016 (which was transmitted to us vide their e-mail dated April 06, 2016), have informed the Company that in the light of the warning letter issued to the Company by the United States Federal Drug Regulatory Authority (US FDA) on January 29, 2016, they have re-assessed the situation and following a risk consideration exercise, will not allocate any volume of Artemisinin based Combination Therapy (ACTs) to the Company and that they will only source ACTs from other pre-qualified suppliers that have no outstanding issues with the regulators". Read more

Strides Shasun: No arbitration proceeding under way between Mylan and Strides
Strides Shasun Ltd has announced that the Exchange vide letter dated April 06, 2016 that; "We refer to the interview with Mr. Rajiv Malik, President of Mylan, published by Economic Times on April 5, 2016 (online edition), in which it was mentioned that Arbitration is going on in London. Read more

Indian pharma industry to face hurdles in US along with currency headwinds in EMs
The Indian pharmaceutical companies have registered strong growth over last decade driven mainly by US market with CAGR of revenue growth from US during FY2011-15 period for our sample set at 33% on back of patent cliff with large brands going off patent and sizeable organic and inorganic expansion. Read more

Aurobindo Pharma receives USFDA nod for Polymyxin B for Injection
Aurobindo Pharma has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Polymyxin B for Injection USP, 500,000 units/vial. This product is expected to be launched in Q2 FY16-17. Read more

Narayana Hrudayalaya ceases hospital operations in Hyderabad
Narayana Hrudayalaya, a leading healthcare service provider in India, today announced that it has decided to cease operations at its "Malla Reddy Narayana Multispecialty Hospital" in Hyderabad, Telangana (erstwhile Andhra Pradesh) and entered into an agreement to sell the undertaking to Chandramma Educational Society. Read more

Glencore in talks to sell agri unit stake to CPPIB
Glencore Plc is in advanced talks to sell a stake in its agricultural business to Canada's largest pension fund as the Swiss commodities giant looks to cut its ~US$26 billion debt burden. Read more

Strides Shasun closes Moberg Pharma deal
Strides Shasun has closed the deal with Moberg Pharma, wherein the Indian pharma major has acquired 3 brands from Moberg for US$ 10 miilion. Read more

Natco Pharma completes sale of SAVE MART
Natco Pharma Limited completed the transaction of sale of its SAVE MART PHARMACY Store located in USA to CARE MART Inc., for which an agreement was executed. Read more

Lupin named among AON Best Employers India 2016
Pharma Major Lupin Limited (Lupin) announced today that it was recognized as AON Best Employers India 2016. Lupin is the only pharmaceutical company on the list this year and part of 25 organizations to feature on the list. Read more

Nayati healthcare lends its support to WHO combating diabetes
Ahead of World Health Day which falls on April 7, Nayati multi super speciality hospital, Mathura announced organising a free health checkup camp for the community on April 7 & 8, 2016. Read more

A gift of good health from PlanMyMedicalTrip.com on World Health Day
A trusted platform that connects patients across geographies to specialised doctors for affordable medical care, PlanMyMedicalTrip.com, has planned a gift of “good health” for people across 9 cities in India on this World Health Day. Read more

Phillips may set up venture fund to back Indian healthcare technology startups
Dutch consumer electronics and healthcare giant Philips is planning to set up a venture fund to invest in Indian health tech startups. By doing this Phillips plans to join the ranks of other global Fortune 500 companies in boosting India's rapidly evolving startup space. Read more

Talwalkars announces launch of 33 Zorba Renaissance Studios
India’s pioneer health & fitness chain, Talwalkars Better Value Fitness Ltd (TBVF) announced the launch of a whopping 33 Zorba renaissance studios across the length and breadth of India. Read more

Lupin names Kurt Nielsen as President of Lupin – Somerset
Lupin announced the appointment of Dr. Kurt Nielsen as President of Lupin – Somerset. Kurt will be responsible for overall operations of the Gavis-Novel Somerset business and will be based out of Somerset, New Jersey. Read more

International News
Pharma in Indonesia: 11th Economic stimulus package issued
On 29/03 the Indonesian government released the11th economic stimulus package with the aim of boosting the domestic production of medicines' raw materials, particularly for five product categories :biotechnology, vaccines, herbal extracts, active pharmaceutical ingredients and medical devices. Read more

FREE Benefits Worth 5,000



Open Demat Account
  • 0

    Per Order for ETF & Mutual Funds Brokerage

  • 20

    Per Order for Delivery, Intraday, F&O, Currency & Commodity